Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FG-B901 Monotherapy and Combination Therapy in Advanced Solid Tumors
NCT07623707Phase 2Not yet recruiting
- Sponsor
- Beijing Mingzhi Zhishan Biotechnology
- Start
- Jul 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of FG-B901 in solid tumor, sponsored by Beijing Mingzhi Zhishan Biotechnology. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
FG-B901
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07623707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07623707.